Endocrine Abstracts

Somatostatin acts as an inhibitor of hormonal secretion and cell proliferation by acting through 5 somatostatin receptors subtypes (sst1–5). Coupling with Gi/o proteins is associated with effects on various transduction pathways, as adenylate cyclase inhibition or phosphatases activation. Dopamine receptor subtype 2 (D2DR) acts through coupling with similar G-proteins and transduction pathways. Sst, mostly sst2 and sst5, are coexpressed with D2DR in many neuroendocrine no...

A 14 year-old Turkish boy sought advice for growth retardation. Pituitary insufficiency with GH, TSH, ACTH and gonadotrophin defect was diagnosed and treated. He was born from a consanguineous family and was married at 24. Three years later he consulted wishing to father a child. He was treated with levothyroxine 150 μg, hGH 0,5 mg/day, hydrocortisone 20 mg/day and was switched from testosterone enantate to hCG+FSH. Azoospermia was initially found and oligospermia after t...

Objective: We describe two first cousins presenting with neonatal corticotropic deficiency and severe, early-onset obesity. This study aims to identify the molecular etiology of these disorders in both cases and highlights the limits of genetic investigations.Methods: We collected the clinical-biological data of the family and, more particularly, of the two first cousins (A and B). We performed several constitutive Next-generation Sequencing (NGS) protoc...

Somatostatin analogs (SSAs) such as octreotide (OCT) are currently effective in controlling most hypersecretion associated symptoms of Gastoenteropancreatic-neuroendocrinetumors (GEP-NETs). The results of the phase IIIb PROMID trial showed that OCT doubled time to progression for patients with metastatic neuroendocrine midgut tumors compared with placebo. SSAs act on different intracellular pathways through different somatostatin receptor (Sst) subtypes. While OCT is mainly an...

Somatotroph adenoma represent 20% of pituitary adenoma. Although often considered as benign, they can induce serious neurological and metabolic complications. GH hypersecretion can be inhibited by somatostatin agonists such as octreotide or lanreotide. However, some GH levels reach normal values in only 50% of treated patiens. The decreased sensitivity to the somatostatin agonists was shown to be related to a lower expression of the sst2 gene.To reverse ...